Drug Trial Radar · NCT05480579
A Study of IBI311 in Healthy Volunteers
Last checked: Nov 19, 2026Latest source record: Oct 11, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
28
Actual
Start
Aug 10, 2022
Primary completion
Nov 23, 2022
Study completion Jan 19, 2023
Sponsor
- Lead sponsor
- Innovent Biologics (Suzhou) Co. Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 29, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
It is designed for Multi-center, double-masked, randomized, placebo- control study with dose escalation phase I trial to evaluate the safety, tolerability, PK and immunogenicity profiles of a single intravenous injection of IBI311 in healthy volunteers.
Conditions
- Healthy
Interventions
placeboBiological
Dose4 placebo of single IV injection
IBI311Biological
Dose2 IBI311 of single IV injection
IBI311Biological
Dose4 IBI311 of single IV injection
placeboBiological
Dose3 placebo of single IV injection
placeboBiological
Dose1 placebo of single IV injection
IBI311Biological
Dose1 IBI311 of single IV injection
IBI311Biological
Dose 3 IBI311 of single IV injection
placeboBiological
Dose2 placebo of single IV injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence, relatedness and severity of all adverse events, treatment emergent adverse events and serious adverse eventsTime frame: Up to 16 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.